Maxim Group Forecasts Strong Price Appreciation for Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare (NASDAQ:SRTS) had its target price raised by Maxim Group from $12.00 to $14.00 in a research note released on Friday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a report on Monday, August 12th.

Sensus Healthcare Stock Performance

Shares of SRTS stock traded up $0.35 during trading hours on Friday, hitting $7.64. The company had a trading volume of 796,533 shares, compared to its average volume of 275,852. Sensus Healthcare has a 12 month low of $2.02 and a 12 month high of $8.29. The firm’s fifty day moving average is $6.37 and its 200 day moving average is $5.94. The firm has a market capitalization of $125.22 million, a price-to-earnings ratio of 18.63 and a beta of 1.04.

Institutional Trading of Sensus Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after acquiring an additional 11,525 shares in the last quarter. XTX Topco Ltd boosted its position in Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare in the 3rd quarter valued at approximately $32,000. Cubist Systematic Strategies LLC bought a new position in shares of Sensus Healthcare in the 2nd quarter valued at about $156,000. Finally, Marshall Wace LLP grew its holdings in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after purchasing an additional 46,732 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.